Sarepta’s stock plunged about 38% in after-hours trading, after it closed the regular session up 1.8%. That decline would put ...

Shares in Sarepta Therapeutics lost nearly 40% of their value after the company said a trial designed to confirm the efficacy ...

"Two of Sarepta’s DMD drugs fail to meet primary endpoint in confirmatory trial" was originally created and published by ...

Comparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression ...

Santhera Pharmaceuticals has announced positive topline results from a long-term analysis of AGAMREE (vamorolone) in patients ...

Sarepta nevertheless plans to push for full FDA approval of Vyondys 53 and Amondys 45 based on what it said are “encouraging ...

Panelists discuss how the pooled 3-year data for delandistrogene moxeparvovec show sustained motor function stabilization and less deterioration compared with natural history, providing confidence in ...

Agamree secured approvals from various nations for Duchenne muscular dystrophy treatment. Credit: MY STOCKERS/Shutterstock.com. Health Canada has approved Santhera Pharmaceuticals’ Agamree (vamorolone ...

People with Duchenne muscular dystrophy have a shorter-than-average life expectancy due to changes in muscles that affect breathing, heart activity, and other functions. However, treatment advances ...

Duchenne muscular dystrophy (DMD) follows an X-linked inheritance pattern. The condition most often affects males, while females may be carriers of the genetic change that causes it. If you have DMD, ...